Navigation Links
World First Medical Treatment Announced by Researchers at Queen,Mary University London and University of Leicester

Breakthrough in Research and Treatment of Rare but Devastating Condition

LONDON, June 1, 2007-Researchers at Queen Mary University London and the University of Leicester and have today (Friday June 1) announced a potential breakthrough in the treatment of a rare but devastating medical condition that can affect children and young people.

In a world first, the clinicians and scientists from the two universities have already treated one patient with promising results. Their preliminary data are published as a letter in the New England Journal of Medicine.

This is the first time research into a condition known as "idiopathic pulmonary haemosiderosis" has investigated the role of 'oxidative stress' and it is also the first time treatment has been carried out based on the research.

Queen Mary University London and the University of Leicester have combined world-class expertise in Child Health, Pulmonary Disease and Oxidative Stress research, plus access to patients with this rare disease. This combination of factors is unique to this collaboration.

Jonathan Grigg, Professor of Paediatric Respiratory and Environmental Medicine at Queen Mary University London, said: "Idiopathic pulmonary haemosiderosis is a rare disease, the cause of which is unknown.

"Affected patients have episodes of bleeding in the lungs, which often need hospital admissions, and in some cases it can be life threatening. This is normally combated by the use of continuous oral steroids (which can have major side effects).

"In a child local to Leicester, we were able to show, for the first time, that there was high levels of oxidative stress in the lungs. In addition, we treated the increased oxidative stress by using of an antioxidant, N-acetyl cysteine - which has no side effects. Since she has been on this treatment she has had no lung bleeds, and the steroid dose has been significantly reduced."'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
2. MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2 Clinical Data at the World Asthma Meeting
3. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
4. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
5. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
6. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
7. Gentiums Defibrotide Highlighted in Poster Presentation at World Congress of Nephrology
8. Onconase has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting
9. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
10. Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in Real World Uses
11. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
Post Your Comments:
(Date:8/21/2008)... Aug. 21 /-,Bayer HealthCar...Inc.,(Nasdaq: ONXX ) today announced the companie...enib as Adjuvant Treatment in the Prevention of,Re...ndomized, double-blind,placebo-controlled Phase 3...s as adjuvant treatment, which is treatment follow...
(Date:8/20/2008)...nobia Pharma, an emerging biotech,company focused ...disorders, today announced that the first patient ...een dosed. Enobia is investigating Enzyme,Replacem...of this rare and,often crippling genetic bone diso...nder two separate protocols, ENB-0040 will be eval...
(Date:8/19/2008)...-,Pharmaceutical company Ph...hat the Phase 3 clinical trial evaluating the long...iectasis has concluded with no serious,adverse eve...treatment., A total of 123 subjects started treat...ubjects completed the full 12 months of the trial....
(Date:8/19/2008)...be used to identify molecular,signature of motor n...ire-USNewswire/ -- ALS Therapy,Development Institu...n ALS,biomarker effort using blood samples collect...ships. These ongoing projects are part of the,Inst...expression of genes,and proteins, at the onset of,...
Breaking Medicine Technology:Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 2Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 3Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 4Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 5Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia 2Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia 312 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis 212 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis 3ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 2ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 3Researchers discover natural herbicide released by grass 1144 1Researchers discover natural herbicide released by grass 1144 2St Jude program reduces weight gain in young African American girls 5856 1St Jude program reduces weight gain in young African American girls 5856 2Skin Cancer Prevention Update 3A 5853 1Skin Cancer Prevention Update 3A 5853 2Skin Cancer Prevention Update 3A 5853 3Skin Cancer Prevention Update 3A 5853 4Skin Cancer Prevention Update 3A 5853 5Feeling Stressed 3F 5850 1Feeling Stressed 3F 5850 2Feeling Stressed 3F 5850 3Feeling Stressed 3F 5850 4
...ased Enzyme Levels in Two Most Common Mutations, C...us,Therapeutics, a biopharmaceutical company devel...logical chaperones for the,treatment of a range of...ill present the results of preclinical studies of,...cher disease at,the of Medical Genetics (ACMG) ann...
...clinical Studies Presented at the Targeted,Antican... Molecular,Targets for Cancer Meetings Support Pha...rch 20, 2007,/PRNewswire-FirstCall/ -- Sunesis Pha...n its development-stage compound, SNS-314, at,two ...ticancer,medicines. Findings from in vitro and in ...
Other Medicine Technology:Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 2Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 3Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor,Data Showing Broad Anti-Tumor Activity, Dosing Flexibility 2Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor,Data Showing Broad Anti-Tumor Activity, Dosing Flexibility 3
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
...ing system for use by physicians predicts early ri...ransient ischemic attack, known as TIA and also ca...out 240,000 TIAs are diagnosed every year in the U...United Kingdom. A TIA is a serious condition cause...
...nase (ADH) is one of the major enzymes involved in...phic at two loci, ADH1B and ADH1C.// The three al...ed with protection from alcohol dependence, a new ...tionship between the ADH1B*3 allele and alcohol-re...
...global acquisitions last year, India's Ranbaxy Lab...the generic drugs business of German// pharmaceuti...llion. ‘We are in talks with private equity funds... executive Malvinder Singh said on the margins of ...
...ochrane Review concluded antidepressants bupropion...es //of giving up smoking and have few side-effect...RIs) such as fluoxetine (Prozac) are not effective...own to help people quit smoking, not everyone is h...
Other Medicine News:Health News:New Tool Improves Prediction of Stroke Risk 2Health News:Alcohol Dehydrogenase Gene may Protect from Developing Alcoholism 2Health News:Alcohol Dehydrogenase Gene may Protect from Developing Alcoholism 3
The QIAamp Viral RNA Mini Kit allows purification of viral nucleic acids from cell-free fluid samples. Examples of viral nucleic acids that can be isolated with this kit include, but are not limited
The PersonalLAB junior is an automated microplate analyzer capable of fully automating immunoenzymatic techniques using a microplate format, per the reagent manufacturer's instruction for use and spe
MAP D-Type can combine a number of assay steps for up to 180 microplates on a simple to use benchtop device. The D-Type base instrument is a multifunctional stand-alone device but also provides easy
Grab one and go, One of the smallest handheld oximeters available, Datex-Ohmeda s TuffSat is the ideal spot-check solution for hospital, home care, transport, and EMS. TuffSat comes fully loaded wi
Medicine Products: